Treeway announces positive data from two separate Phase I TW001 clinical trials
Successful dose and confirmatory study solid platform for phase II/III trial in ALS patients. Read more here.…
Trial News & Events
Treeway to collaborate on developing AAV5-GDNF gene therapy for ALS
Treeway is pleased to announce a collaboration with the Cedars-‐Sinai Board of Governors Regenerative Medicine Institute for the development of AAV5-‐GDNF (TW002) gene therapy for ALS. Read more here.…
Answer ALS + NFL Game-Changing Moments
"The NFL has had 1000s of game changers, ALS only needs 1." Watch here.…
Tar Heel: Duke Dr. Richard Bedlack collecting new ideas to fight ALS
Bedlack founded and directs Duke University’s ALS Clinic, which takes an unusual interdisciplinary approach to helping ease the suffering and extend the lives of patients with this fatal disease. Read more here.…
FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of
(November 9, 2015) This is an Open-Label, Proof-of-Mechanism, Phase 2a trial of ibudilast in ALS patients. Read more here.…
Federal funding secured for Barrow-TGen advanced technology study of Amyotrophic Lateral Sclerosis
Multi-year study of patients seeks biomarkers that can provide early detection and progression of Lou Gehrig's disease. Read more here.…
BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial
The study was designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors. Read more here.…
Magnet Test Finds Cortex Overexcitable in All ALS
Scientists know that in people with some forms of amyotrophic lateral sclerosis, the motor cortex springs into action more often than it should. Now researchers conclude that the same occurs in people with ALS due to the C9ORF72 expansion. Read more here.…
Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital Announce Groundbreaking AL
Today, the launch of an Amyotrophic Lateral Sclerosis research project of Answer ALS, the largest single coordinated and comprehensive effort to end ALS, was announced. Read more here.…
NEALS Research Ambassador, Brian Parsons, on compassionate care
Parsons, 49, has successfully lobbied for rights of families of terminally ill patients. Read more here.…